Medroxyprogesterone Acetate

醋酸甲羟孕酮

Report date: 2026/02/24 20:00:16
NME

Base Information

Drug NameMedroxyprogesterone Acetate
Drug Alias Name醋酸甲孕酮Depo subQ in Uniject安宫黄体酮DMPA -PfizerMedroxiprogesterone acetate +[23] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionProgesterone receptor agonists
TargetsProgesterone receptor
Therapy Area/IndicationsContraceptionAmenorrheaNeurodermatitis +[18] 
Global Approved IndicationsAmenorrheaUterine HemorrhageProstatic Neoplasms +[6] 
Approved Indications in ChinaProstatic NeoplasmsEndometrial NeoplasmsBreast Neoplasms +[4] 
Original Approved Country/TerritoryUnited States
Original Approved Date1959/06/18
Country/TerritoryZambiaUnited StatesThailand +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesKyowa Kirin Co LtdPfizer IncTianjin Pharmaceutical Research Institute Co Ltd +[4] 
Inactive CompaniesWyeth LlcOffice Of Research And Women'S Health (Orwh)University Of California San Francisco +[11] 
Active IndicationsContraceptionAmenorrheaNeurodermatitis +[11] 
Inactive IndicationsLupus Erythematosus, SystemicCoronary DiseaseHeart Diseases +[7] 

Other Information

ATC CodeG03AC06G03DA02L02AB02
Related LinksWikipediaDrugBankKEGG